donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > BLUE bluebird bio > Key Indicators
BLUE bluebird bio
4.280
+0.140+3.38%
Post Mkt Price
4.28000.00%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
-- -- -- -- -- -- -- 2.9178
Receivable Turnover(T)
-97.78% 0.2597 -98.48% 0.1917 -98.48% 0.1917 -82.81% 2.1138
Inventory Turnover(T)
-- -- -- -- -- -- -- 63.7807
Fixed Assets Turnover(T)
-97.15% 0.0194 -97.77% 0.0163 -97.77% 0.0163 -74.17% 0.1895
Total Asset Rate(T)
-97.1% 0.0044 -97.84% 0.0031 -97.84% 0.0031 -74.93% 0.0327
ROIC
-79.9% -82.722% -96.6% -81.539% -96.6% -81.539% -61.71% -62.533%
ROE
-87.59% -100.536% -102.18% -94.762% -102.18% -94.762% -68.38% -72.211%
ROA
-76% -69.135% -95.65% -68.999% -95.65% -68.999% -57.21% -52.613%
Efficiency Ratios
ROE 5 Year Average
-- -- -34.49% -50.010% -- -- -- --
ROA 5 Year Average
-- -- -29.64% -38.620% -- -- -- --
Average 5 Years ROIC
-- -- -31.78% -44.648% -- -- -- --
Profitability Ratios TTM
Gross Margin
-1013.71% -888.564% -1082.23% -961.087% -1082.23% -961.087% -90.88% 8.937%
Operating Margin
-4129.98% -11444.133% -6046.42% -15431.731% -6046.42% -15431.731% -519.16% -1618.973%
Net Margin
-5966.18% -15610.482% -8967.81% -22375.150% -8967.81% -22375.150% -527.14% -1610.781%
EBITDA Margin
-4138.56% -111.1944% -6020.91% -148.9517% -6020.91% -148.9517% -521.74% -15.7738%
R & D Expense Ratio
2645.3% 6683.170% 3625.92% 8736.920% 3625.92% 8736.920% 331.05% 1056.290%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Long-Term Debt to Equity Ratio
117.65% 32.222% 43.17% 17.749% 43.17% 17.749% 53.78% 17.475%
Total Assets to Common Equity
36.75% 186.535% 20.69% 158.651% 20.69% 158.651% 20.47% 153.889%
Debt to Asset Ratio
144.5% 41.912% 68.03% 23.935% 68.03% 23.935% 62.66% 20.857%
Current Ratio
-66.46% 1.784 -63.16% 2.1996 -63.16% 2.1996 -52.46% 3.1225
Quick Ratio
-68.94% 1.5615 -64.88% 2.0321 -64.88% 2.0321 -52.97% 3.0044
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -164.53% -59.365% -- -- -- --
Revenue CAGR(5Y)
-- -- -112.67% -9.864% -- -- -- --
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company’s clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with β-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
CEO: Obenshain, Andrew
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...